The moderating role of resilience in the relationship between experiences of COVID-19 response-related discrimination and disinformation among people who inject drugs.


Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 05 2023
Historique:
received: 05 05 2022
revised: 27 02 2023
accepted: 28 02 2023
medline: 25 4 2023
pubmed: 17 3 2023
entrez: 16 3 2023
Statut: ppublish

Résumé

Due to the persistence of COVID-19, it remains important to measure and examine potential barriers to COVID-19 prevention and treatment to avert additional loss of life, particularly among stigmatized populations, such as people who inject drugs (PWID), who are at high risk for contracting and spreading SARS-CoV-2. We assessed the psychometrics of a novel COVID-19 response-related discrimination scale among PWID, and characterized associations between COVID-19 response-related discrimination, resilience to adversity, and endorsement of COVID-19 disinformation. We assessed internal reliability, structural validity and construct validity of a 4-item COVID-19 response-related discrimination scale among PWID living in San Diego County, completing interviewer-administered surveys between October 2020 and September 2021. Using negative binomial regression, we assessed the relationship between COVID-19 response-related discrimination and disinformation and the potential moderating role of resilience. Of 381 PWID, mean age was 42.6 years and the majority were male (75.6 %) and Hispanic (61.9 %). The COVID-19 response-related discrimination scale had modest reliability (α = 0.66, ω = 0.66) as a single construct with acceptable construct validity (all p ≤ 0.05). Among 216 PWID who completed supplemental surveys, a significant association between COVID-19 response-related discrimination and COVID-19 disinformation was observed, which was moderated by resilience (p = 0.044). Specifically, among PWID with high levels of resilience, endorsement of COVID-19 disinformation significantly increased as exposure to COVID-19 response-related discrimination increased (p = 0.011). These findings suggest that intervening on COVID-19 response-related discrimination may offset the negative outcomes associated with COVID-19 disinformation.

Sections du résumé

BACKGROUND
Due to the persistence of COVID-19, it remains important to measure and examine potential barriers to COVID-19 prevention and treatment to avert additional loss of life, particularly among stigmatized populations, such as people who inject drugs (PWID), who are at high risk for contracting and spreading SARS-CoV-2. We assessed the psychometrics of a novel COVID-19 response-related discrimination scale among PWID, and characterized associations between COVID-19 response-related discrimination, resilience to adversity, and endorsement of COVID-19 disinformation.
METHODS
We assessed internal reliability, structural validity and construct validity of a 4-item COVID-19 response-related discrimination scale among PWID living in San Diego County, completing interviewer-administered surveys between October 2020 and September 2021. Using negative binomial regression, we assessed the relationship between COVID-19 response-related discrimination and disinformation and the potential moderating role of resilience.
RESULTS
Of 381 PWID, mean age was 42.6 years and the majority were male (75.6 %) and Hispanic (61.9 %). The COVID-19 response-related discrimination scale had modest reliability (α = 0.66, ω = 0.66) as a single construct with acceptable construct validity (all p ≤ 0.05). Among 216 PWID who completed supplemental surveys, a significant association between COVID-19 response-related discrimination and COVID-19 disinformation was observed, which was moderated by resilience (p = 0.044). Specifically, among PWID with high levels of resilience, endorsement of COVID-19 disinformation significantly increased as exposure to COVID-19 response-related discrimination increased (p = 0.011).
CONCLUSIONS
These findings suggest that intervening on COVID-19 response-related discrimination may offset the negative outcomes associated with COVID-19 disinformation.

Identifiants

pubmed: 36924661
pii: S0376-8716(23)00069-8
doi: 10.1016/j.drugalcdep.2023.109831
pmc: PMC9981478
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

109831

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA055521
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA049644
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH123282
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflict of interest.

Références

Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Psychol Bull. 1995 Nov;118(3):392-404
pubmed: 7501743
Soc Sci Med. 2008 Aug;67(3):358-67
pubmed: 18524444
AIDS Behav. 2020 Oct;24(10):2776-2780
pubmed: 32440972
Lancet. 2006 Feb 11;367(9509):528-9
pubmed: 16473129
J Behav Med. 2013 Jun;36(3):270-82
pubmed: 22526525
Int J Health Serv. 2014;44(4):643-710
pubmed: 25626224
J Acquir Immune Defic Syndr. 2021 Feb 1;86(2):200-207
pubmed: 33196555
J Racial Ethn Health Disparities. 2022 Aug;9(4):1430-1442
pubmed: 34117633
Front Psychol. 2020 Oct 23;11:566790
pubmed: 33192844
Bull World Health Organ. 2007 Nov;85(11):867-72
pubmed: 18038077
Int J Equity Health. 2021 Jan 6;20(1):14
pubmed: 33407521
J Int AIDS Soc. 2020 Jul;23(7):e25583
pubmed: 32697423
PLoS Med. 2019 Nov 26;16(11):e1002969
pubmed: 31770387
Psychol Assess. 2016 Jan;28(1):51-8
pubmed: 26146948
JAMA Psychiatry. 2022 Sep 1;79(9):898-906
pubmed: 35895053
Am J Public Health. 2021 Jul;111(S2):S73-S74
pubmed: 34314215
PLoS One. 2021 Nov 22;16(11):e0260286
pubmed: 34807963
J Anxiety Disord. 2020 Oct;75:102289
pubmed: 32853884
Health Aff (Millwood). 2022 Feb;41(2):171-178
pubmed: 35130057
Lancet Infect Dis. 2020 Jul;20(7):782
pubmed: 32592670
J Clin Psychiatry. 2006 Feb;67(2):247-57
pubmed: 16566620
Clin Infect Dis. 2022 Aug 24;75(1):e726-e733
pubmed: 35024825
Int J Behav Med. 2008;15(3):194-200
pubmed: 18696313
Soc Sci Med. 2020 Oct;263:113356
pubmed: 32967786
Am J Public Health. 2022 Mar;112(3):401-404
pubmed: 35196050
BMJ Open. 2021 Nov 2;11(11):e048241
pubmed: 34728443
Harm Reduct J. 2020 May 6;17(1):26
pubmed: 32375887
Epidemiol Psychiatr Sci. 2022 May 26;31:e37
pubmed: 35616053
Br J Psychol. 2014 Aug;105(3):399-412
pubmed: 24844115
J Int AIDS Soc. 2020 May;23(5):e25504
pubmed: 32365283
J Multidiscip Healthc. 2021 Nov 10;14:3125-3134
pubmed: 34795485

Auteurs

Angel B Algarin (AB)

Center for Health Promotion and Disease Prevention, Edson College of Nursing and Health Innovation, Arizona State University - Downtown Campus, Phoenix, AZ, USA.

Samantha Yeager (S)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.

Thomas L Patterson (TL)

Department of Psychiatry, University of California San Diego, San Diego, CA, USA.

Steffanie A Strathdee (SA)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.

Alicia Harvey-Vera (A)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA; Facultad de Medicina, Universidad Xochicalco, Tijuana, Mexico; United States-Mexico Border Health Commission, Tijuana, Mexico.

Carlos F Vera (CF)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.

Tara Stamos-Buesig (T)

Harm Reduction Coalition of San Diego, San Diego, CA, USA.

Irina Artamanova (I)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.

Daniela Abramovitz (D)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.

Laramie R Smith (LR)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA. Electronic address: laramie@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH